Inhibrx Biosciences (INBX) Amortization of Deferred Charges (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Amortization of Deferred Charges data on file, last reported at $642000.0 in Q4 2025.

• On a quarterly basis, Amortization of Deferred Charges changed N/A year-over-year to $642000.0 in Q4 2025; TTM through Dec 2025 was $2.4 million, a 18.11% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 18.11% from the prior year.
• Amortization of Deferred Charges for Q4 2025 stood at $642000.0, up from $638000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for INBX reached as high as $1.2 million in Q4 2023 and fell as low as $533000.0 in Q1 2025.
• Historically, Amortization of Deferred Charges has averaged $873750.0 across 3 years, with a median of $732500.0 in 2024.
• On a YoY basis, Amortization of Deferred Charges climbed as much as 23.94% in 2025 and fell as far as 57.09% in 2025.
• Year by year, Amortization of Deferred Charges stood at $1.2 million in 2023, then tumbled by 34.0% to $823000.0 in 2024, then decreased by 21.99% to $642000.0 in 2025.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $642000.0 in Q4 2025, $638000.0 in Q3 2025, and $626000.0 in Q2 2025.